Koru Medical Systems, Inc. (KRMD) Stock Price & Analysis
Koru Medical Systems, Inc. (KRMD) rose 2.68% to USD 3.83 as of July 25, 2026 at 09:05 UTC, according to Nexqual real-time market data.
KRMD last closed at USD 3.73; the session ranged USD 3.71–3.89 on volume of 194,626 shares. Market capitalization is $175.92M, with a 52-week range of USD 3.2–6.61 (NCM). Source: Nexqual, July 25, 2026 at 09:05 UTC.
Key Statistics (as of July 25, 2026 at 09:05 UTC)
| Price | USD 3.83 |
|---|---|
| Change | ▲ 2.68% (up) |
| Previous Close | USD 3.73 |
| Open | USD 3.73 |
| Day Range | USD 3.71 – 3.89 |
| 52-Week Range | USD 3.2 – 6.61 |
| Volume | 194,626 shares |
| Market Cap | $175.92M |
| Exchange | NCM |
Technical Analysis (KRMD)
Nexqual's technical model rates KRMD "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.81 (neutral) |
| vs SMA50 | Below (USD 4.1) |
| MACD | -0.08 (negative) |
Analyst Ratings (KRMD)
Wall Street analysts rate KRMD "None" based on 5 analysts, with a mean price target of USD 6.8 (range USD 5–8), per Nexqual as of July 25, 2026 at 09:05 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 6.8 |
| High Target | USD 8 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (KRMD)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $11.62M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0 vs est -0.01 ▲ beat |
| 2025-12-31 | USD 0.01 vs est -0.01 ▲ beat |
| 2025-09-30 | USD 0 vs est -0.02 ▲ beat |
| 2025-06-30 | USD 0.01 vs est -0.02 ▲ beat |
Source: Nexqual, July 25, 2026 at 09:05 UTC.
Financials & Fundamentals (KRMD)
| Total Revenue | $43.26M |
|---|---|
| Revenue Growth (YoY) | +22.10% |
| Gross Margin | +61.93% |
| Operating Margin | -7.35% |
| Profit Margin | -5.27% |
| ROE | -13.70% |
| Debt / Equity | 19.89 |
| Current Ratio | 2.33 |
| Total Cash | $8.77M |
| Total Debt | $3.37M |
| Free Cash Flow | $874,285 |
Source: Nexqual, July 25, 2026 at 09:05 UTC.
Financial Health Score (KRMD)
Nexqual rates Koru Medical Systems, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 09:05 UTC.
| Growth | Strong — Revenue +22% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $9M cash vs $3M debt, net cash position |
| Cash Flow | Mixed — FCF $874K, slim 2.1% margin |
| Efficiency | Critical — ROE -14%, ROA -5.8% |
Ownership (KRMD)
| Insider Ownership | +8.01% |
|---|---|
| Institutional Ownership | +57.02% |
| Shares Outstanding | 45.93M |
| Float | 34.15M |
| Short % of Float | +2.14% |
Source: Nexqual, July 25, 2026 at 09:05 UTC.
Leadership (KRMD)
Koru Medical Systems, Inc. is led by Adam Kalbermatten (age 41), President & CEO, per Nexqual as of July 25, 2026 at 09:05 UTC.
| President & CEO | Adam Kalbermatten (age 41) |
|---|---|
| CFO, Secretary & Treasurer | Thomas Adams (age 52) |
| Chief Operating Officer | Christopher Pazdan (age 42) |
| Chief Technology Officer | Eric Schiller (age 51) |
Major Backers & Investors (KRMD)
Notable institutional backers of Koru Medical Systems, Inc. include First Light Asset Management, LLC, Topline Capital Management, LLC, Simcoe Capital LLC, according to Nexqual as of July 25, 2026 at 09:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Light Asset Management, LLC | 9.45% |
| Topline Capital Management, LLC | 8.81% |
| Simcoe Capital LLC | 2.03% |
| Meros Investment Management, Lp | 1.91% |
| Empire Financial Management Company, LLC | 1.76% |
| Fidelity | 1.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.63% |
| Vanguard Group | 8.86% |
| Geode Capital | 2.64% |
| State Street | 1.63% |
Source: Nexqual, July 25, 2026 at 09:05 UTC.
From Koru Medical Systems, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- The SCIg products administered by the FREEDOM System are indicated for a variety of conditions, including Primary Immunodeficiency Disease (PIDD ) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the United States and PIDD, CIDP and Secondary Immunodeficiency Disorder ("SIDD") outside of the United States.
- The use of the FREEDOM System for SCIg drug delivery continues to increase, and it remains the market leading delivery system in the U.S. for these treatments.
Partnerships
- The Company does not have any contracts with suppliers that impose material binding obligations on the Company or provide the Company with any material rights or benefits, other than the Company's agreement with Command.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IRMD | iRadimed Corporation | USD 94.49 | ▲ 0.44% |
| APYX | Apyx Medical Corporation | USD 3.92 | ▲ 0.26% |
| TELA | TELA Bio, Inc. | USD 0.69 | ▼ 5.73% |
| ELMD | Electromed, Inc. | USD 38.41 | ▼ 2.81% |
| INFU | InfuSystems Holdings, Inc. | USD 9.12 | ▲ 2.47% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:05 UTC. This page is informational and not investment advice.